Drugs / Sar 56 kDa
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00287469 | Jul 2001 → Jan 2004 | hepatitis E virus infection | U.S. Army Medical Research and Development Command | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sar 56 kDa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00287469 ↗ |
| Known as | rhE Sar 56 kDa | “20mcg or rhE Sar 56 kDa/dose of 0.5 mL, aluminium hydroxide (0.5 mg/dose) and phenoxyethanol (2.5 mg/dose)” NCT00287469 ↗ |
| Modality | Protein / enzyme biologic | “HEV recombinant protein (rHEV) vaccine” PMID 17329696 ↗ Mar 2007 |
| Route | Intramuscular | “20mcg of recombinant HEV antigen administered intramuscularly in the deltoid” NCT00287469 ↗ |